Lingjing Xue
- Biomedical Engineering top 2%
- Molecular Biology top 10%
- Biomaterials top 0.5%
- Immunology top 5%
- Oncology top 10%
- Topics
- Nanoplatforms for cancer theranostics (18 papers)RNA Interference and Gene Delivery (14 papers)Nanoparticle-Based Drug Delivery (12 papers)
- Journals
- Journal of the American Chemical SocietyAdvanced MaterialsAngewandte Chemie International Edition
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Lingjing Xue
52 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Biomedical Engineering 1.4k
- Molecular Biology 1.2k
- Biomaterials 1.2k
- Immunology 658
- Oncology 386
Countries citing papers authored by Lingjing Xue
This map shows the geographic impact of Lingjing Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingjing Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingjing Xue more than expected).
Fields of papers citing papers by Lingjing Xue
This network shows the impact of papers produced by Lingjing Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingjing Xue. The network helps show where Lingjing Xue may publish in the future.
Co-authorship network of co-authors of Lingjing Xue
This figure shows the co-authorship network connecting the top 25 collaborators of Lingjing Xue. A scholar is included among the top collaborators of Lingjing Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingjing Xue. Lingjing Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 24 | |
| 4 | 14 | |
| 5 | 4 | |
| 6 | 20 | |
| 7 | 13 | |
| 8 | 142 | |
| 9 | 69 | |
| 10 | 24 | |
| 11 | 10 | |
| 12 | 39 | |
| 13 | 74 | |
| 14 | 11 | |
| 15 | 41 | |
| 16 | 108 | |
| 17 | 61 | |
| 18 | 32 | |
| 19 | 8 | |
| 20 | 205 |
About Lingjing Xue
Lingjing Xue is a scholar working on Biomaterials, Immunology and Oncology, having authored 53 papers that have together received 2.8k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (18 papers), RNA Interference and Gene Delivery (14 papers) and Nanoparticle-Based Drug Delivery (12 papers). The work is most often cited by research in Biomaterials (1.2k citations), Biomedical Engineering (1.4k citations) and Immunology (658 citations). Lingjing Xue has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Can Zhang, Ran Mo, Caoyun Ju, Hongbin Sun, Qineng Ping, Jingwei Xue, Zhigui Su, Zekai Zhao, Lingyi Kong and Yajing Wen. Their work appears in journals such as Journal of the American Chemical Society, Advanced Materials and Angewandte Chemie International Edition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.